|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC186 |
Gene summary for CCDC186 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC186 | Gene ID | 55088 |
| Gene name | coiled-coil domain containing 186 | |
| Gene Alias | C10orf118 | |
| Cytomap | 10q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0001678 | UniProtAcc | Q496Y1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55088 | CCDC186 | LZE2T | Human | Esophagus | ESCC | 1.55e-02 | 2.89e-01 | 0.082 |
| 55088 | CCDC186 | LZE4T | Human | Esophagus | ESCC | 7.36e-14 | 3.54e-01 | 0.0811 |
| 55088 | CCDC186 | LZE5T | Human | Esophagus | ESCC | 1.34e-03 | 4.97e-01 | 0.0514 |
| 55088 | CCDC186 | LZE7T | Human | Esophagus | ESCC | 9.04e-08 | 4.56e-01 | 0.0667 |
| 55088 | CCDC186 | LZE8T | Human | Esophagus | ESCC | 5.34e-11 | 2.00e-01 | 0.067 |
| 55088 | CCDC186 | LZE20T | Human | Esophagus | ESCC | 1.35e-09 | 1.15e-01 | 0.0662 |
| 55088 | CCDC186 | LZE24T | Human | Esophagus | ESCC | 3.42e-29 | 7.79e-01 | 0.0596 |
| 55088 | CCDC186 | LZE21T | Human | Esophagus | ESCC | 3.69e-02 | 2.73e-01 | 0.0655 |
| 55088 | CCDC186 | P1T-E | Human | Esophagus | ESCC | 7.85e-11 | 5.47e-01 | 0.0875 |
| 55088 | CCDC186 | P2T-E | Human | Esophagus | ESCC | 5.43e-34 | 7.20e-01 | 0.1177 |
| 55088 | CCDC186 | P4T-E | Human | Esophagus | ESCC | 2.65e-25 | 6.13e-01 | 0.1323 |
| 55088 | CCDC186 | P5T-E | Human | Esophagus | ESCC | 7.22e-22 | 5.57e-01 | 0.1327 |
| 55088 | CCDC186 | P8T-E | Human | Esophagus | ESCC | 3.17e-24 | 4.85e-01 | 0.0889 |
| 55088 | CCDC186 | P9T-E | Human | Esophagus | ESCC | 2.16e-09 | 1.68e-01 | 0.1131 |
| 55088 | CCDC186 | P10T-E | Human | Esophagus | ESCC | 4.62e-19 | 1.55e-01 | 0.116 |
| 55088 | CCDC186 | P11T-E | Human | Esophagus | ESCC | 2.69e-07 | 5.40e-01 | 0.1426 |
| 55088 | CCDC186 | P12T-E | Human | Esophagus | ESCC | 1.83e-38 | 7.56e-01 | 0.1122 |
| 55088 | CCDC186 | P15T-E | Human | Esophagus | ESCC | 9.23e-19 | 4.27e-01 | 0.1149 |
| 55088 | CCDC186 | P16T-E | Human | Esophagus | ESCC | 1.18e-33 | 6.43e-01 | 0.1153 |
| 55088 | CCDC186 | P17T-E | Human | Esophagus | ESCC | 4.35e-11 | 3.45e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:005165016 | Esophagus | ESCC | establishment of vesicle localization | 114/8552 | 161/18723 | 8.20e-11 | 2.53e-09 | 114 |
| GO:003070518 | Esophagus | ESCC | cytoskeleton-dependent intracellular transport | 133/8552 | 195/18723 | 1.48e-10 | 4.27e-09 | 133 |
| GO:005164815 | Esophagus | ESCC | vesicle localization | 119/8552 | 177/18723 | 5.16e-09 | 1.08e-07 | 119 |
| GO:00995185 | Esophagus | ESCC | vesicle cytoskeletal trafficking | 50/8552 | 73/18723 | 6.75e-05 | 5.12e-04 | 50 |
| GO:000930617 | Esophagus | ESCC | protein secretion | 190/8552 | 359/18723 | 3.22e-03 | 1.34e-02 | 190 |
| GO:003559217 | Esophagus | ESCC | establishment of protein localization to extracellular region | 190/8552 | 360/18723 | 3.77e-03 | 1.53e-02 | 190 |
| GO:007169210 | Esophagus | ESCC | protein localization to extracellular region | 193/8552 | 368/18723 | 5.01e-03 | 1.92e-02 | 193 |
| GO:0009743111 | Esophagus | ESCC | response to carbohydrate | 135/8552 | 253/18723 | 8.16e-03 | 2.89e-02 | 135 |
| GO:00097437 | Liver | NAFLD | response to carbohydrate | 45/1882 | 253/18723 | 1.07e-04 | 2.11e-03 | 45 |
| GO:00425936 | Liver | NAFLD | glucose homeostasis | 45/1882 | 258/18723 | 1.71e-04 | 3.08e-03 | 45 |
| GO:00335006 | Liver | NAFLD | carbohydrate homeostasis | 45/1882 | 259/18723 | 1.87e-04 | 3.29e-03 | 45 |
| GO:00342847 | Liver | NAFLD | response to monosaccharide | 37/1882 | 225/18723 | 1.86e-03 | 1.91e-02 | 37 |
| GO:00307055 | Liver | NAFLD | cytoskeleton-dependent intracellular transport | 33/1882 | 195/18723 | 1.98e-03 | 1.98e-02 | 33 |
| GO:00097467 | Liver | NAFLD | response to hexose | 36/1882 | 219/18723 | 2.14e-03 | 2.08e-02 | 36 |
| GO:00516565 | Liver | NAFLD | establishment of organelle localization | 57/1882 | 390/18723 | 2.52e-03 | 2.34e-02 | 57 |
| GO:00516485 | Liver | NAFLD | vesicle localization | 30/1882 | 177/18723 | 3.01e-03 | 2.72e-02 | 30 |
| GO:00355926 | Liver | NAFLD | establishment of protein localization to extracellular region | 52/1882 | 360/18723 | 4.80e-03 | 3.81e-02 | 52 |
| GO:00516505 | Liver | NAFLD | establishment of vesicle localization | 27/1882 | 161/18723 | 5.47e-03 | 4.20e-02 | 27 |
| GO:00016786 | Liver | NAFLD | cellular glucose homeostasis | 28/1882 | 172/18723 | 7.15e-03 | 4.96e-02 | 28 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC186 | SNV | Missense_Mutation | c.775N>C | p.Glu259Gln | p.E259Q | Q7Z3E2 | protein_coding | tolerated(0.11) | probably_damaging(0.997) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCDC186 | SNV | Missense_Mutation | rs758664195 | c.1943N>A | p.Arg648Gln | p.R648Q | Q7Z3E2 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCDC186 | SNV | Missense_Mutation | rs757447418 | c.1292N>A | p.Arg431Gln | p.R431Q | Q7Z3E2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCDC186 | SNV | Missense_Mutation | novel | c.999N>T | p.Glu333Asp | p.E333D | Q7Z3E2 | protein_coding | tolerated(0.05) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCDC186 | SNV | Missense_Mutation | novel | c.2191N>T | p.Asn731Tyr | p.N731Y | Q7Z3E2 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-AQ-A54N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC186 | insertion | Nonsense_Mutation | novel | c.1758_1759insTAATACAAATATATTCAGATATTTGCCATAGAGTTTAGTTTGTTTTTA | p.Ser586_Glu587insTer | p.S586_E587ins* | Q7Z3E2 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| CCDC186 | SNV | Missense_Mutation | rs759611860 | c.829G>A | p.Val277Ile | p.V277I | Q7Z3E2 | protein_coding | tolerated(0.32) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CCDC186 | SNV | Missense_Mutation | c.583N>C | p.Glu195Gln | p.E195Q | Q7Z3E2 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.714) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| CCDC186 | SNV | Missense_Mutation | c.1522C>G | p.Leu508Val | p.L508V | Q7Z3E2 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CCDC186 | SNV | Missense_Mutation | novel | c.410C>T | p.Ser137Leu | p.S137L | Q7Z3E2 | protein_coding | deleterious_low_confidence(0.02) | benign(0.133) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |